TPCW
PTCT icon

TD Private Client Wealth’s PTC Therapeutics PTCT Stock Holding History

TD Private Client Wealth’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Hold
148
– – ﹤0.01% 1099
2025
Q4 		$11.2K Sell
148
-204
-58% -$14.8K ﹤0.01% 1078
2025
Q3 		$21.6K Buy
+352
New +$18.3K ﹤0.01% 974

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TD Private Client Wealth's PTCT Position: Q1 2026 in Review

TD Private Client Wealth held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 148 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

TD Private Client Wealth first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $21.6K in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • TD Private Client Wealth held 148 shares of PTC Therapeutics worth $10.1K as of Q1 2026.
  • TD Private Client Wealth left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #1099 holding.
  • TD Private Client Wealth first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • TD Private Client Wealth's PTC Therapeutics position peaked at $21.6K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.